Literature DB >> 6186271

beta-thromboglobulin and platelet factor 4 levels in retinal vein occlusion.

P M Dodson, J Westwick, G Marks, V V Kakkar, D J Galton.   

Abstract

Fifty-six patients with retinal vein occlusion--35 with central and 21 with branch vein occlusion--were investigated for comparison with an age and sex matched control group. Mean levels of beta-thromboglobulin and platelet factor 4 were significantly higher (p less than 0.001) in both the group with central and the group with branch retinal vein occlusion than in the control group. A significant increase of beta-thromboglobulin (p less than 0.001) was also found in the retinal vein occlusion group in those patients who were not hyperlipidaemic or diabetic (n = 39). Weak correlations were found between levels of lipoprotein cholesterol and plasma beta-thromboglobulin. Increased platelet aggregation may contribute to the aetiology of retinal vein occlusion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186271      PMCID: PMC1039996          DOI: 10.1136/bjo.67.3.143

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  A survey of the pathogenesis of retinal venous occlusion, emphasis upon choice of therapy and an analysis of the therapeutic results in fifty-three patients.

Authors:  B A KLIEN; J H OLWIN
Journal:  AMA Arch Ophthalmol       Date:  1956-08

2.  Occlusion of the central retinal vein; clinical importance of certain histopathologic observations.

Authors:  B A KLIEN
Journal:  Am J Ophthalmol       Date:  1953-03       Impact factor: 5.258

3.  The fluorometric assay of triglyceride by a semiautomated method.

Authors:  D G Cramp; G Robertson
Journal:  Anal Biochem       Date:  1968-10-24       Impact factor: 3.365

Review 4.  Atherogenesis and thrombosis.

Authors:  J E French
Journal:  Semin Hematol       Date:  1971-01       Impact factor: 3.851

5.  The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4.

Authors:  J Dawes; R C Smith; D S Pepper
Journal:  Thromb Res       Date:  1978-05       Impact factor: 3.944

6.  Retinal vein occlusion and the prevalence of lipoprotein abnormalities.

Authors:  P M Dodson; D J Galton; A M Hamilton; R K Blach
Journal:  Br J Ophthalmol       Date:  1982-03       Impact factor: 4.638

7.  Platelet function in diabetes mellitus in relationship to complications, glycosylated haemoglobin and serum lipoproteins.

Authors:  D J Betteridge; J Zahavi; N A Jones; B Shine; V V Kakkar; D J Galton
Journal:  Eur J Clin Invest       Date:  1981-08       Impact factor: 4.686

8.  Impending central retinal vein occlusion associated with increased platelet aggregability.

Authors:  I A Priluck
Journal:  Ann Ophthalmol       Date:  1979-01

9.  Evidence for the platelet specificity of beta-thromboglobulin and studies on its plasma concentration in healthy individuals.

Authors:  C A Ludlam
Journal:  Br J Haematol       Date:  1979-02       Impact factor: 6.998

10.  Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia.

Authors:  J Zahavi; J D Betteridge; N A Jones; D J Galton; V V Kakkar
Journal:  Am J Med       Date:  1981-01       Impact factor: 4.965

View more
  13 in total

Review 1.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

Review 2.  Management of retinal vein occlusion.

Authors:  P M Dodson; E E Kritzinger
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-05

3.  Retinal vessel responses to systemic autonomic stimulation in fellow eyes of patients with retinal vein occlusion.

Authors:  L P Lanigan; C V Clark; D W Hill
Journal:  Doc Ophthalmol       Date:  1990 Apr-Jul       Impact factor: 2.379

4.  Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.

Authors:  T H Williamson; A Rumley; G D Lowe
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

5.  Medical conditions underlying retinal vein occlusion in patients with glaucoma or ocular hypertension.

Authors:  M D Cole; P M Dodson; S Hendeles
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

6.  Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion.

Authors:  S Boyd; D Owens; T Gin; K Bunce; H Sherafat; D Perry; P G Hykin
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

7.  Medical conditions underlying recurrence of retinal vein occlusion.

Authors:  P M Dodson; A J Kubicki; K G Taylor; E E Kritzinger
Journal:  Br J Ophthalmol       Date:  1985-07       Impact factor: 4.638

8.  Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis.

Authors:  Ning Cheung; Ronald Klein; Jie Jin Wang; Mary Frances Cotch; Amirul F M Islam; Barbara E K Klein; Mary Cushman; Tien Yin Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-06       Impact factor: 4.799

9.  Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients.

Authors:  R F Walters; D J Spalton
Journal:  Br J Ophthalmol       Date:  1990-01       Impact factor: 4.638

10.  The mean platelet volume in patients with retinal vein occlusion.

Authors:  Alparslan Sahin; Muhammed Sahin; Harun Yüksel; Fatih Mehmet Türkcü; Yasin Cınar; Abdullah Kürşat Cingü; Seyhmus Arı; Ihsan Caça
Journal:  J Ophthalmol       Date:  2013-05-28       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.